NCT05440929 Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
| NCT ID | NCT05440929 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Condition | Metastatic Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2022-07-07 |
| Primary Completion | 2027-08-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2022-07-07 with a primary completion date of 2027-08-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 10 participants). The investigators will code the qualitative data using emerging themes, guided by a well-established implementation science theory, the Consolidated Framework for Implementation Research (CFIR). The information gained from these studies will inform an implementation approach to increase the usability and acceptability of a novel prognostic tool to assist oncologists in the prognosis of patients with metastatic breast cancer.
Eligibility Criteria
Inclusion Criteria: 1. Verbal informed consent obtained to participate in the study. 2. Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee. 3. Physician, nurse practitioner, physician assistant, or nurse navigator 4. At least 6 months of experience in the clinical care of patients with metastatic breast cancer in the United States. Exclusion Criteria: * Non-English Speaking
Contact & Investigator
Emily Ray, MD
PRINCIPAL INVESTIGATOR
University of North Carolina, Chapel Hill
Frequently Asked Questions
Who can join the NCT05440929 clinical trial?
This trial is open to participants of all sexes, studying Metastatic Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05440929 currently recruiting?
Yes, NCT05440929 is actively recruiting participants. Contact the research team at teubanks@med.unc.edu for enrollment information.
Where is the NCT05440929 trial being conducted?
This trial is being conducted at Chapel Hill, United States.
Who is sponsoring the NCT05440929 clinical trial?
NCT05440929 is sponsored by UNC Lineberger Comprehensive Cancer Center. The principal investigator is Emily Ray, MD at University of North Carolina, Chapel Hill. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.